Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
193.45
+2.07 (1.08%)
At close: May 8, 2026, 4:00 PM EDT
194.25
+0.80 (0.41%)
After-hours: May 8, 2026, 7:27 PM EDT
Biogen Employees
Biogen had 7,500 employees as of December 31, 2025. The number of employees decreased by 105 or -1.38% compared to the previous year.
Employees
7,500
Change (1Y)
-105
Growth (1Y)
-1.38%
Revenue / Employee
$1,324,987
Profits / Employee
$182,920
Market Cap
28.56B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,500 | -105 | -1.38% |
| Dec 31, 2024 | 7,605 | 35 | 0.46% |
| Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
| Dec 31, 2022 | 8,725 | -885 | -9.21% |
| Dec 31, 2021 | 9,610 | 510 | 5.60% |
| Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
| Dec 31, 2019 | 7,400 | -400 | -5.13% |
| Dec 31, 2018 | 7,800 | 500 | 6.85% |
| Dec 31, 2017 | 7,300 | -100 | -1.35% |
| Dec 31, 2016 | 7,400 | 50 | 0.68% |
| Dec 31, 2015 | 7,350 | -200 | -2.65% |
| Dec 31, 2014 | 7,550 | 700 | 10.22% |
| Dec 31, 2013 | 6,850 | 900 | 15.13% |
| Dec 31, 2012 | 5,950 | 950 | 19.00% |
| Dec 31, 2011 | 5,000 | 150 | 3.09% |
| Dec 31, 2010 | 4,850 | 100 | 2.11% |
| Dec 31, 2009 | 4,750 | 50 | 1.06% |
| Dec 31, 2008 | 4,700 | 400 | 9.30% |
| Dec 31, 2007 | 4,300 | 550 | 14.67% |
| Dec 31, 2006 | 3,750 | 410 | 12.28% |
| Dec 31, 2005 | 3,340 | -926 | -21.71% |
| Dec 31, 2004 | 4,266 | 539 | 14.46% |
| Feb 20, 2004 | 3,727 | 2,732 | 274.57% |
| Jan 31, 2003 | 995 | 303 | 43.79% |
| Jan 31, 2002 | 692 | 199 | 40.37% |
| Jan 31, 2001 | 493 | 86 | 21.13% |
| Jan 31, 2000 | 407 | 42 | 11.51% |
| Jan 31, 1999 | 365 | 26 | 7.67% |
| Dec 31, 1997 | 339 | 71 | 26.49% |
| Dec 31, 1996 | 268 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| Bristol-Myers Squibb Company | 32,500 |
| Amgen | 31,500 |
BIIB News
- 2 days ago - Eisai, Biogen announce FDA extension of review period for lecanemab-irmb sBLA - TheFly
- 2 days ago - Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease - PRNewsWire
- 2 days ago - Remitly Global to replace Apellis in S&P 600 at open on 5/14 - TheFly
- 2 days ago - Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600 - PRNewsWire
- 2 days ago - Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates - Business Wire
- 9 days ago - Biogen upgraded to Buy from Hold at Freedom Broker - TheFly
- 9 days ago - Biogen price target raised to $190 from $189 at Truist - TheFly
- 9 days ago - Biogen price target raised to $200 from $190 at Citi - TheFly